A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT06134375
Recruiting
There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer. In the phase 1b part of the study, TM is added to adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer (RCB 2, 3, risk for relapse \>60% at 5 years) after completion o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Triple Negative Breast Cancer, Residual Disease
Register for Updates
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777
Recruiting
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/20/2025
Locations: Yale University, New Haven, Connecticut +9 locations
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
05/20/2025
Locations: Research Site, Palmdale, California +83 locations
Conditions: Severe Asthma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
NCT06679959
Recruiting
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/20/2025
Locations: Ascletis clinical site, San Antonio, Texas
Conditions: Chronic Weight Management
Register for Updates
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
NCT06824350
Recruiting
The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care facilities on maternal and neonatal health. Intervention facilities will receive a passive chlorination technology for water supply treatment and a reliable supply of sodium hypochlorite disinfectant. Both intervention and treatment facilities will receive infection preven... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/20/2025
Locations: University of California, Berkeley, Berkeley, California +1 locations
Conditions: Sepsis, Neonatal Mortality, Antibiotic Resistant Infection, Enteric Infections, Serious Bacterial Infection
Register for Updates
Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds
NCT06984835
Recruiting
The study will be a prospective, randomized, multi-center, split-face, controlled, double-blind clinical trial to evaluate the safety and effectiveness of ELLANSÉ®-S for the treatment of NLFs. Subjects will be randomized to receive treatment (ELLANSÉ®-S) in one NLF and control (Radiesse®) in the contralateral NLF. A total of 126 subjects will be treated. The control and test articles will be supplied in sterile ready-to-use, pre-filled syringes. Initial treatment and any 4-week touch-up will be... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/20/2025
Locations: Investigate MD, Scottsdale, Arizona +6 locations
Conditions: Nasolabial Folds
Register for Updates
Interventions for Patients With Alzheimer's Disease and Dysphagia
NCT03682081
Recruiting
The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
05/20/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Dementia, Dysphagia, Alzheimer Disease
Register for Updates
Lung Ultrasound Artefact Analysis for Exclusion of Acute Rejection in Lung Transplant Recipients
NCT04582279
Recruiting
This study is being done to study a safe and non-invasive way to diagnose lung rejection and infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Post-Lung Transplantation Bronchiectasis
Register for Updates
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT05239546
Recruiting
This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of Iowa Hospitals & Clinics, Iowa City, Iowa
Conditions: Colon Cancer, DMMR Colorectal Cancer
Register for Updates
A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli
NCT05606575
Recruiting
Nelli is a video-based non-EEG physiological seizure monitoring system. This study is a blinded comparison of Nelli's identified events to gold-standard video EEG review in at-rest pediatric subjects with suspected motor seizures.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
05/20/2025
Locations: The University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Epilepsy
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2025
Locations: Research Site, Dothan, Alabama +794 locations
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
NCT06157099
Recruiting
This clinical trial tests whether atorvastatin prevents metastasis of resected high-risk stage IIA, IIB or IIIA melanoma. The vast majority of melanomas are diagnosed at an early, localized stage. However, approximately 10-15% of these localized melanomas will eventually metastasize, despite appropriate local treatment. Once metastasis occurs, median survival is less than two years. Melanomas at high risk of metastasis can be identified by gene expression profiling. Statin drugs, like atorvastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8
Register for Updates